Last update 21 Nov 2024

AK-001

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
Siglec-8
Mechanism
Siglec-8 inhibitors(Sialic acid-binding Ig-like lectin 8 inhibitors), Immunomodulators
Therapeutic Areas
Otorhinolaryngologic DiseasesRespiratory DiseasesImmune System Diseases+ [2]
Active Indication-
Inactive Indication
Dermatitis, AtopicNasal Polyps
Originator Organization
Allakos, Inc.Allakos, Inc.
Active Organization-
Inactive Organization
Allakos, Inc.Allakos, Inc.
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with AK-001
NCT02734849 / CompletedPhase 2
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis
NCT02563938 / CompletedPhase 1
A Phase 1, Randomized, Double-Blind, Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 in Subjects With Atopic Disease
100 Clinical Results associated with AK-001
Login to view more data
100 Translational Medicine associated with AK-001
Login to view more data
100 Patents (Medical) associated with AK-001
Login to view more data
100 Deals associated with AK-001
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nasal PolypsPhase 2
ES
Allakos, Inc.Allakos, Inc.
01 Apr 2016
Nasal PolypsPhase 2
NL
Allakos, Inc.Allakos, Inc.
01 Apr 2016
Nasal PolypsPhase 2
US
Allakos, Inc.Allakos, Inc.
01 Apr 2016
Nasal PolypsPhase 2
BE
Allakos, Inc.Allakos, Inc.
01 Apr 2016
Nasal PolypsPhase 2
DE
Allakos, Inc.Allakos, Inc.
01 Apr 2016
Nasal PolypsPhase 2
GB
Allakos, Inc.Allakos, Inc.
01 Apr 2016
Dermatitis, AtopicPhase 2
US
Allakos, Inc.Allakos, Inc.
01 Sep 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02734849 (CTgov)
Phase 2
Nasal Polyps
40
(25 mg AK001)
nsaqiwmauf(jtlqwwlsru) = sdtjfhqtde ltpnwaogyg (kiklwueukd, fcgwpqqoee - vherhpcmww)
View more
-
28 Dec 2020
(250 mg AK001)
nsaqiwmauf(jtlqwwlsru) = uuumpqjspa ltpnwaogyg (kiklwueukd, ohiprdfmls - moijcuxehy)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free